Highest-materiality recent filing
Janux Q1 2026 net loss $24.4M; cash $956.4M; discontinues JANX008, initiates JANX014
Net loss of $24.4M for Q1 2026 vs $23.5M YoY; cash and investments at $956.4M.
Janux reports FY2025 net loss $113.6M; cash $966.6M; BMS collaboration with $50M upfront
Cash and short-term investments $966.6M at Dec 31, 2025, down from $1.03B a year ago.
Janux licenses tumor-activated therapeutic to BMS for solid tumors; up to $800M milestones
Upfront $15M and near-term milestone $35M; total milestones up to ~$800M.
Janux Q1 net loss $23.5M; initiates JANX007 Phase 1b expansion in mCRPC
Initiated Phase 1b expansion with JANX007 in taxane-naïve mCRPC; updated median rPFS 7.5 months (n=16).
Janux Therapeutics reports FY2024 net loss $69M, cash $1.03B, positive JANX007 data
Cash and short-term investments $1.03B at year-end 2024, up from $344M in 2023, largely from $402.5M December offering.
Janux Therapeutics prices $350M public offering of common stock and pre-funded warrants
Priced 5,317,460 shares at $63.00/share and pre-funded warrants for 238,095 shares at $62.999
Janux reports positive interim JANX007 data; selects doses for Phase 1b expansion in mCRPC
100% of 16 patients achieved PSA50 declines; 63% PSA90; 31% PSA99 declines.
Janux Q2 2024 net loss $6.0M; cash $646.3M; receives $7.5M Merck milestone
Net loss of $6.0M vs $17.5M in Q2 2023; improvement driven by $7.5M milestone payment from Merck.
Jay Lichter, Ph.D. resigned from the board effective July 19, not due to any disagreement.
Janux Therapeutics Q1 2024: Cash $651.8M; net loss $14.8M; trials ongoing
Cash and short-term investments $651.8M as of March 31, 2024, up from $344.0M at Dec 31, 2023.
Janux reports $344M year-end cash; Q4 net loss $11.8M; positive Phase 1 JANX007/JANX008 data
Year-end cash & investments $344M; net loss $58.3M for FY 2023 vs $63.1M in 2022.
Janux Therapeutics prices $296.5M public offering of common stock and pre-funded warrants
Pricing: 4,440,851 shares at $46.50/share and pre-funded warrants to purchase 1,935,483 shares at $46.499.
Janux reports positive interim Phase 1a data for PSMA-TRACTr and EGFR-TRACTr; cash at $338.2M
At JANX007 starting dose ≥0.2 mg, 6/6 (100%) achieved PSA30 and 5/6 (83%) PSA50; one PSA90 observed.
Janux announces encouraging safety/efficacy data for JANX007 in mCRPC and JANX008 in solid tumors
JANX007: 5/6 (83%) PSA50 declines at step dose ≥0.2 mg; 10/18 (56%) at ≥0.1 mg; no Grade 3+ CRS.
Janux Q2 net loss $17.5M; cash $303.3M; Nasdaq compliance regained
Net loss of $17.5M for Q2 2023 vs. $16.9M in Q2 2022; R&D expense $14.9M, G&A $6.9M.
Janux Therapeutics prices $60M underwritten offering of common stock and pre-funded warrants
Priced 4,153,717 shares at $12.46/share and pre-funded warrants for 583,483 shares at $12.459 each.
Janux reports ~$304M cash; JANX007 interim data show PSA drops 31-67% in 4/5 patients
Preliminary cash, equivalents, and short-term investments ~$304.1M as of June 30, 2023.
Janux Therapeutics CMO Wayne Godfrey resigns; Chief Strategy Officer Byron Robinson interim lead
Dr. Wayne Godfrey resigns as CMO effective July 5, 2023 for personal reasons; no disagreement with company.
Janux loses majority-independent board after director exit; Nasdaq grants cure period
Independent director Peter Thompson did not stand for re-election, reducing independent directors to 4 out of 9 total.
Janux Q1 net loss $17.5M; first patient dosed with JANX008 in Phase 1
Cash and equivalents $316.9M, down from $327.0M at Dec 31, 2022.
Janux Q3 net loss $16.7M; first patient dosed in JANX007 Phase 1 trial
Q3 2022 net loss of $16.7M vs $10.8M prior year; R&D spend $13.7M (up from $8.4M).
Janux Therapeutics reports Q2 net loss of $16.9M; IND cleared for lead candidate JANX007
Net loss $16.9M vs $6.2M in Q2 2021; R&D expenses rose to $14.1M from $4.7M.
Janux Q1 net loss $13.4M; cash $361.2M; IND filed for JANX007
Net loss of $13.4M for Q1 2022 vs. $2.3M in Q1 2021; R&D spend $10.2M, G&A $4.9M.
Cash, cash equivalents and short-term investments $375.0M at Dec 31, 2021, vs $7.8M a year ago.
Janux reports Q3 net loss of $10.8M, cash $387.5M; IND filings on track for 2022
Cash and equivalents $387.5M at Sept 30, 2021, up from $7.8M at Dec 31, 2020.
Janux Therapeutics Q2 net loss $6.2M; cash $394.2M post $222.9M IPO
Completed $222.9M IPO in June and $125.0M Series B in April, total $347.9M in quarter.
In connection with Dr. Lichter’s resignation, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), Ron Barrett, Ph.D. was appointed as Chair of the Board.
On July 19, 2024, Jay Lichter, Ph.D. resigned as a member of the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), including his chairmanship of the Board, effective as of such date.
On July 19, 2024, the Board, upon the recommendation of the Nominating and Governance Committee, appointed (i) Natasha Hernday as a Class II director of the Company, with a term of office expiring at the Company’s 2026 annual meeting of stockholders, or until her earlier death, resignation or removal.
and (ii) Eric Dobmeier as a Class III director of the Company, with a term of office expiring at the Company’s 2027 annual meeting of stockholders, or until his earlier death, resignation or removal.
On June 21, 2023, Wayne Godfrey, M.D. resigned from his position as Chief Medical Officer of Janux Therapeutics, Inc. (the “Company”), effective July 5, 2023.
On an interim basis and effective immediately, Byron Robinson, Ph.D., the Company’s Chief Strategy Officer, will take over leadership of the Company’s ongoing clinical activities and supervise the Company’s experienced clinical team.
On March 27, 2023, Peter Thompson, M.D., a director of Janux Therapeutics, Inc. (the “Company”), informed the Company that he does not intend to stand for re-election as a member of the Board of Directors at the Company’s 2023 annual meeting of stockholders as a result of competing commitments.
Also on September 21, 2022, Stefan Heller, Ph.D., resigned as a member of the Board effective as of such date.
On September 21, 2022, the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), appointed Winston Kung as a Class I director of the Company
appointed (i) Ronald Barrett, Ph.D. as a Class I director of the Company, with a term of office expiring at the 2022 annual meeting of stockholders, and (ii) Alana McNulty as a Class II director of the Company, with a term of office expiring at the 2023 annual meeting of stockholders.
appointed (i) Ronald Barrett, Ph.D. as a Class I director of the Company, with a term of office expiring at the 2022 annual meeting of stockholders, and (ii) Alana McNulty as a Class II director of the Company, with a term of office expiring at the 2023 annual meeting of stockholders.
Max materiality 0.90 · Median 0.60 · Most common event earnings